CeriBell (CBLL) Q1 2026 Earnings Transcript

CeriBell reported Q1 revenue of $26.5 million, up 29% year over year and 7% sequentially, while raising full-year 2026 revenue guidance to $112 million-$116 million from $111 million-$115 million. Gross margin held at 87%, account count rose to 680 hospitals with 33 net additions, and management highlighted record headband utilization plus launches in neonate, pediatric, and delirium monitoring. Offsetting the positive operating momentum, operating expenses rose 36% to $43.9 million, including $5.6 million of litigation-related G&A, though management expects legal costs to moderate later in 2026.

Analysis

The key read-through is that CBLL is transitioning from a single-product adoption story to a multi-indication platform story, and that materially changes the comp set. If management is right, the near-term driver is not just more hospitals, but higher penetration per install as delirium, neonate, and pediatrics create a broader clinical workflow; that typically supports multiple years of above-consensus utilization growth even if new-logo additions become lumpier. The market should also start valuing the company less like an early commercial medtech and more like a reimbursement-enabled workflow platform, which can justify a richer multiple if the reimbursement catalyst clears.

The second-order winner is likely CMS-aligned hospitals that can monetize NTAP early, because the proposed incremental payment reduces adoption friction and should pull forward purchasing decisions ahead of the October effective date. That matters especially in regional systems and VA/military settings where procurement is centralized: once one facility validates the workflow, system-level rollout can accelerate faster than a pure territory-by-territory model. The less obvious loser is competing bedside neurologic monitoring approaches that rely on intermittent or labor-intensive workflows; they now face a narrowing window before CBLL’s evidence package, reimbursement, and multi-indication narrative harden into a stronger moat.

The biggest risk is that the current optimism outruns the actual cadence of revenue recognition. Guidance still depends heavily on conversion timing and utilization, while seasonality, litigation spend, and the lag between pilot wins and full rollout could create a sequence where headline demand looks strong but quarterly numbers wobble. If the reimbursement rule slips, or if the added indications fail to meaningfully lift same-store utilization by late 2026, the stock could de-rate quickly because the current setup assumes a smooth path to a larger TAM and higher monetization.

Contrarian take: the market may be underestimating how much of the upside is actually in 2027, not 2026. This quarter’s data are good, but the real leverage comes when multi-site systems, VA penetration, and delirium pricing all stack together; that is a longer-duration story than the tape may currently discount. Near term, the stock could be prone to disappointment if investors extrapolate record Q1 usage straight through the softer Q2/Q3 seasonal window.

Key Decisions for Investors

• Long CBLL into the next 3-6 months on dips below post-earnings support, targeting a catalyst stack from the August CMS final rule and Q3 account conversions; risk/reward is attractive if reimbursement is affirmed and the market starts pricing 2027 revenue acceleration.
• Buy CBLL call spreads expiring after the August CMS decision to express upside from reimbursement while capping premium at risk; use strikes that benefit from a re-rating rather than an aggressive beat-and-raise.
• Pair trade: long CBLL / short a slower-growth hospital workflow or monitoring name over 6-9 months to isolate the multi-indication reimbursement catalyst versus a pure utilization story; this should work if CBLL’s category leadership translates into premium multiple expansion.
• If already long, trim 20-30% into any sharp post-earnings pop and re-add after Q2/Q3 seasonally weaker prints; the best entry is likely when the market misreads sequential moderation as a demand slowdown rather than normal seasonality.